ProfileGDS5678 / 1455887_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 63% 63% 67% 62% 62% 61% 62% 65% 63% 63% 68% 62% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5259258
GSM967853U87-EV human glioblastoma xenograft - Control 23.7354463
GSM967854U87-EV human glioblastoma xenograft - Control 33.7393763
GSM967855U87-EV human glioblastoma xenograft - Control 44.1240667
GSM967856U87-EV human glioblastoma xenograft - Control 53.6871762
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7622162
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7330861
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7198362
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8750765
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7347763
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7428663
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2121568
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7208862
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.731363